Valuation: Madrigal Pharmaceuticals, Inc.

Market Cap 12.09B 10.47B 9.9B 8.96B 16.83B 1,160B 16.95B 118B 45.46B 588B 45.41B 44.4B 1,875B P/E 2026 *
-82.9x
P/E 2027 * 83.1x
Enterprise Value 11.56B 10.02B 9.47B 8.58B 16.1B 1,109B 16.22B 113B 43.49B 563B 43.44B 42.48B 1,794B EV / Sales 2026 *
7.58x
EV / Sales 2027 * 5.2x
Free-Float
94.12%
Yield 2026 *
-
Yield 2027 * -
1 day-3.11%
1 week-2.04%
Current month-3.11%
1 month+3.09%
3 months+4.70%
6 months+17.63%
Current year-10.15%
1 week 513.36
Extreme 513.36
546.56
1 month 506.29
Extreme 506.29
552.08
Current year 416.21
Extreme 416.21
598.79
1 year 393.6
Extreme 393.605
615
3 years 119.76
Extreme 119.7604
615
5 years 52.33
Extreme 52.33
615
10 years 9.87
Extreme 9.87
615
Manager TitleAgeSince
Chief Executive Officer 59 2023-09-07
Director of Finance/CFO 62 2024-03-10
Chief Tech/Sci/R&D Officer 58 2025-04-20
Director TitleAgeSince
Director/Board Member 74 2016-06-30
Director/Board Member 68 2016-08-10
Director/Board Member 64 2019-06-26
Date Insider Type Main position Quantity % Market Cap. Importance
9/11/26 Sell

Chief Executive Officer

-5,221 0.0226%
8/17/26 Sell

General Counsel

-664 0.0029%
8/15/26 Free

Director

1,725 0.0075%
Change 5-day change 1-year change 3-year change Capi.($)
-3.11%-2.04%+22.95%+197.49% 12.48B
-1.38%+0.20%+46.42%+96.33% 70.24B
-1.04%-0.81%+34.61%+75.16% 62.63B
-4.29%-3.98%-16.22%+350.66% 27.36B
+1.79%+2.48%+29.13%+14.79% 25.71B
-2.20%-2.00%-1.22%-14.48% 24.83B
+1.61%-0.69%+20.85%-19.42% 19.52B
+1.26%-14.23%+170.04%+298.75% 15.51B
-5.54%+0.69%-8.13%+830.48% 14.69B
-0.95%-4.66%-10.25%+452.53% 14.66B
Average -1.38%-2.18%+28.82%+228.23% 28.76B
Weighted average by Cap. -1.29%-1.35%+30.47%+162.17%

Financials

2026 *2027 *
Net sales 1.53B 1.32B 1.25B 1.13B 2.12B 146B 2.14B 14.92B 5.74B 74.24B 5.73B 5.61B 237B 2.14B 1.86B 1.76B 1.59B 2.99B 206B 3.01B 20.97B 8.07B 104B 8.06B 7.88B 333B
Net income -184M -159M -151M -136M -256M -17.64B -258M -1.8B -691M -8.94B -691M -675M -28.52B 200M 173M 164M 148M 278M 19.18B 280M 1.95B 752M 9.73B 751M 735M 31.02B
Net Debt -525M -454M -430M -389M -730M -50.31B -735M -5.13B -1.97B -25.51B -1.97B -1.93B -81.36B -943M -817M -773M -699M -1.31B -90.48B -1.32B -9.22B -3.55B -45.88B -3.54B -3.46B -146B
Logo Madrigal Pharmaceuticals, Inc.
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. The Company’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-b agonist designed to target key underlying causes of MASH. Rezdiffra is the medication approved by the United States Food and Drug Administration (FDA) for the treatment of MASH with moderate to advanced fibrosis (consistent with stages F2 to F3). Rezdiffra is a prescribed medicine used along with diet and exercise to treat adults with nonalcoholic steatohepatitis (NASH) with moderate to advanced liver scarring (fibrosis), but not with cirrhosis of the liver. An ongoing Phase III outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (consistent with stage F4c).
Employees
915
Date Price Change Volume
26-09-15 US$523.26 -3.11% 259,410
26-09-14 US$540.06 +1.04% 156,535
26-09-11 US$534.49 +0.26% 187,643
26-09-10 US$533.12 -2.48% 225,766
26-09-09 US$546.66 +2.34% 281,255
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
523.26USD
Average target price
678.06USD
Spread / Average Target
+29.58%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. MDGL Stock
LAST HOURS | 40% Discount: The Best Subscriber-Only Tools to Unlock Hidden Opportunities!
d
:
:
SEIZE THE OFFER!